Alcon opens the week with a full earnings calendar, shares steady ahead of next update
29.06.2026 - 13:03:40 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-29, 13:03.
Alcon (CH0432492467) starts the week with a clearly outlined earnings and investor-relations calendar for the coming quarters. The eye-care group is listed on the SIX Swiss Exchange in Zurich, making the stock a regular component of many European healthcare portfolios as earnings dates approach.
Upcoming earnings and IR events
According to the company's investor relations website, Alcon typically reports quarterly results on a fixed rhythm, with second-quarter figures usually scheduled for late summer and third-quarter numbers in the autumn, accompanied by conference calls for analysts and investors. The quarterly results section of Alcon's IR site lists recent reports and indicates that the next update will follow this established pattern.
In addition to earnings calls, Alcon maintains a calendar of participation in healthcare conferences and investor meetings where management discusses strategy and performance with institutional investors. These recurring events, documented on the IR calendar, provide regular touchpoints for market participants to reassess their models and expectations. The events and presentations overview on Alcon's site shows recent conference appearances and upcoming slots.
Consensus view and analyst focus
Analyst coverage continues to focus on Alcon's mid-single-digit organic sales growth ambition in both Surgical and Vision Care and on incremental margin improvement over the mid term, as reflected in recent consensus data compiled by market platforms. While individual targets differ, the majority of international healthcare analysts track the stock with a neutral to positive stance, pointing to the company's exposure to stable ophthalmology demand. Consensus data on MarketScreener for Alcon shows a broad spread of price targets but a clustered recommendation picture.
Recent notes from large houses such as UBS and JPMorgan, as reported in financial media coverage over the past months, have highlighted Alcon's position in premium intraocular lenses and contact lenses as a driver for resilient cash flows. These research views typically stress the relatively defensive profile of surgical ophthalmology compared with more cyclical areas of medtech, keeping the stock on watch lists even in volatile phases for indices such as the SMI and Stoxx Europe 600 Health Care. A prior Reuters healthcare sector piece mentioning Alcon illustrates this focus.
All news and analysis on the Alcon shares
Track earnings releases, analyst notes and sector moves around Alcon in one place on ad-hoc-news.de and via the company's investor relations hub.
How Alcon earns its money
Alcon generates most of its revenue from ophthalmic surgical devices and equipment as well as contact lenses and lens care products within its Vision Care division. The surgical portfolio includes phacoemulsification machines, intraocular lenses and consumables used in cataract and refractive procedures, while Vision Care provides daily disposable and reusable contact lenses along with solutions and drops for end consumers.
Where the stock trades today
Alcon shares trade on the SIX Swiss Exchange in Zurich under the ticker ALC. As of 2026-06-29, 11:00, the stock is quoted around 75.00 Swiss francs, according to recent price data from the Swiss exchange.
Alcon at a glance
- Company: Alcon Inc
- ISIN: CH0432492467
- WKN: A2P2BE
- Ticker: ALC
- Trading venue: SIX Swiss Exchange
- Price (as of 2026-06-29, 11:00): 75.00 CHF
- Market cap: approximately 37.0 billion CHF (as of 2026-06-29)
- Sector / industry: Health Care - Medical Equipment and Supplies
- Index membership: SMI and Stoxx Europe 600 Health Care
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
